Skip To Main Content
Adam Jourdan on Muck Rack

Adam Jourdan

Verified
  • EMEA Companies News Editor, Reuters
Buenos Aires
As seen in: Reuters, Brasil Online, MSN, MSN Canada, MSN Malaysia, MSN Money Canada, MSN Singapore, MSN UK, O Globo, The New York Times, UOL and
Reuters Bureau Chief in south Latin America. Based in Buenos Aires. Ex China. Husband and dad to three sproglets. England/Scotland. Tips: adam.jourdan@tr.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Adam

Contact Adam, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Exclusive-AirBaltic in talks with unions to cut workers amid restructuring, CEO says

|
By Adam Jourdan Verified, Joanna Plucinska Verified, Susan Fenton Verified
| Westlaw Today Verified
We've updated our Privacy Statement. Before you continue, please read our new Privacy Statement and familiarize yourself with the terms.
Open in Who Shared View Duplicates (205) Issue with article?

Nestle looks to develop new products to serve users of weight-loss drugs

|
By Richa Naidu Verified, Adam Jourdan Verified, Matt Scuffham Verified
| Think Pink (Podcast)
The rapid adoption of drugs made by Novo Nordisk and Eli Lilly has fuelled investor concerns that appetite-suppressing medicines could permanently reduce demand for packaged foods, snacks and beverages International News via Reuters: Nestle is seeking to turn the rise of GLP-1 weight-loss drugs from a threat into a business opportunity, using artificial intelligence and nutritional science to develop products aimed at millions of consumers taking medicines such as Ozempic and Wegovy.
Open in Who Shared View Duplicates (141) Issue with article?

Novo CEO looks to speed up R&D as share drop shows gap with Lilly

|
By Maggie Fick Verified, Elaine Hardcastle, Adam Jourdan Verified
| Westlaw Today Verified
We've updated our Privacy Statement. Before you continue, please read our new Privacy Statement and familiarize yourself with the terms.
Open in Who Shared View Duplicates (665) Issue with article?
See all 3,947 licensed articles (4,256 Total)